- Home
- LGI vs OBIO Comparison
LGI vs OBIO Comparison
Compare LGI & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | OBIO |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.0M | 246.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LGI | OBIO |
|---|---|---|
| Price | $17.59 | $4.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 63.8K | ★ 143.8K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $13.95 | $2.20 |
| 52 Week High | $19.88 | $5.42 |
Technical Indicators
Market Signals| Indicator | LGI | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 56.47 |
| Support Level | $17.19 | $4.02 |
| Resistance Level | $17.75 | $4.88 |
| Average True Range (ATR) | 0.35 | 0.24 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 96.71 | 76.47 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.